IDG will present its work at the 13th Annual NIH CAP FeedForward(TM) Sessions. We thank the LARTA Institute for this opportunity and welcome mentor feedback! http://www.larta.org      

The Company’s novel approach in matching the infecting bug with the correct drug the first time has been covered by Modern Healthcare: Innovations. Please read the entire text here: http://www.modernhealthcare.com/article/20170204/MAGAZINE/302049981

ID Genomics, Inc. has launched a first of its kind initiative that brings together clinical partners in an effort to combat antibiotic resistance worldwide. Covered by GenomeWeb, please read more about our efforts here: https://www.genomeweb.com/molecular-diagnostics/id-genomics-launches-consortium-improve-infectious-disease-diagnostics

SEATTLE (January 11, 2026) ID Genomics, Inc. announced the formation of a national consortium of clinical partners to help increase the rapidity and accuracy of infectious disease diagnosis and antibiotic treatment through the company’s novel DNA-based “bacterial fingerprinting” diagnostics system. The initial consortium was formed under a grant from National Institutes of Health and includes the Group Health Cooperative, Seattle Children’s Research Institute and Harborview Medical Center in Seattle; Los Angeles County Medical Center and

ID Genomics’ CEO, Dr. Kaveri Parker, will present the Company’s technology and its implications for the American warfighter at the Defense Innovation Challenge in Austin, TX. Please come visit our showcase exhibit at booth 313W in Griffin Hall at the JW Marriott. http://defenseinnovation.us

As the recipient of a $3 million, 3-year Phase II SBIR grant, ID Genomics has been selected for the Commercialization Acceleration Program sponsored by the National Institutes of Health and the Larta Institute. The goal of this program is to assist early stage companies in commercializing their technology by expanding their network to include experts in industry, finance, and regulation. IDG was selected as one of seventy six (76) companies from submissions across the US.

ID Genomics, Inc. has been selected as an Innovation Challenge company by the Redefining Early Stage Investments (RESI) Conference in Boston, MA. Please come visit our poster and learn more about the conference here: http://www.resiconference.com/resi-boston-2016/

IDG is pleased to announce the appointment of Mansour Samadpour, Ph.D. to our Board of Directors. Dr. Samadpour serves as the President and Chief Executive Officer at Molecular Epidemiology, Inc. and Institute for Environmental Health, Inc. Together, these companies form the largest food- and water-safety testing organization in the United States. With 130 ISO certified laboratories in the U.S., Dr. Samadpour has has more than two decades of experience in the successful commercialization of numerous diagnostic products relevant to microbiology,